Streetbeat News

VASO

Vaso Corp

https://vasocorporation.com/

CEO

Jun Ma

Employees

256

Industry

Surgical and Medical Instrument Manufacturing

Open

0.13

Mkt cap

23M

Volume

75K

High

0.13

P/E Ratio

6.50

52-wk high

0.35

Low

0.13

Div yield

N/A

52-wk low

0.12

Vaso Corporation reported revenue growth in Q3 2024, but faced higher costs and a net loss, impacting profitability. Despite these challenges, VASO stock saw an increase.

Portfolio Pulse from

November 18, 2024 | 6:15 pm

Vaso Corporation reported its financial results for the third quarter of 2024, highlighting its diversified business in medtech, network and healthcare IT services, professional sales services, and proprietary medical products.

Portfolio Pulse from

November 14, 2024 | 2:15 pm

VASO Corporation reported Q2 revenue of $20.226 million, a slight decrease from $20.323 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:05 pm

Vaso, a medical technology company, is set to list on Nasdaq through a SPAC merger, valuing the company at a pro forma equity value of $176 million, with a share price of $10.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 10:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.